Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett's esophagus

Digestive Diseases and Sciences

Volumn 57, Issue 10, 2012, Pages 2625-2632

  Akiyama, Junichi ^a,b   Marcus, Samuel N ^a,b   Triadafilopoulos, George ^a,b  

^a El Camino GI Medical Associates   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acid suppression; Barrett's esophagus; Fundoplication; pH Monitoring; Proton pump inhibitors; Radiofrequency ablation

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; DISEASE SEVERITY; ENDOSCOPY; ESOPHAGEAL ACID EXPOSURE; ESOPHAGEAL PH MONITORING; EXPOSURE; FEMALE; HUMAN; INTRA ESOPHAGEAL PH CONTROL; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL RECORD REVIEW; METAPLASIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY;

AGED; BARRETT ESOPHAGUS; CATHETER ABLATION; COHORT STUDIES; FEMALE; FUNDOPLICATION; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 84867852978     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2313-2     Document Type: Article

References (34)

1. Altorki NK, Oliveria S, Schrump DS. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin Surg Oncol. 1997;13:270-280.
2. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery. 1957;41:881-894.
3. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996;110: 614-621.
4. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287-1289.
5. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol. 2003;98:1627-1633.
6. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology. 1999;117:327-335.
7. Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther. 2006;23:727-733.
8. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut. 1999;45:489-494.
9. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol. 1994;89:1844-1848.
10. Yeh RW, Triadafilopoulos G. Endoscopic therapy for Barrett's esophagus. Gastrointest Endosc Clin N Am. 2005;15:377-397.
11. Fleischer D, Overholt B, Sharma V, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008;68:867-876.
12. Ganz R, Overholt B, Sharma V, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc. 2008;68:35-40.
13. Pouw R, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010;8:23-29.
14. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277-2288.
15. Sharma V, Jae Kim H, Das A, Wells C, Nguyen C, Fleischer D. Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol. 2009;104:310-317.
16. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther. 2004;20:637-643.
17. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1998;93:711-716.
18. Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96:2005-2012.
19. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131: 1392-1399.
20. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668-685.
21. Matthews HR. A proposed classification for hiatal hernia and gastroesophageal reflux. Dis Esophagus. 1996;9:1-3.
22. Yeh RW, Gerson LB, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus. Dis Esophagus. 2003;16:193-198.
23. Lidums I, Holloway R. Motility abnormalities in the columnarlined esophagus. Gastroenterol Clin North Am. 1997;26: 519-531.
24. Johnson DA, Winters C, Spurling TJ, Chobanian SJ, Cattau EL. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol. 1987;9:23-27.
25. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7-12.
26. Stein HJ, Hoeft S, DeMeester TR. Functional foregut abnormalities in Barrett's esophagus. J Thorac Cardiovasc Surg. 1993; 105:107-111.
27. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus. 2007; 20:516-522.
28. Basu KK, Pick B, Bale R, West KP, de Caestecker JS. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut. 2002;51:776-780.
29. Kahaleh M, Van Laethem J-L, Nagy N, Cremer M, Devière J. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy. 2002;34:950-955.
30. Ferraris R, Fracchia M, Foti M, et al. Barrett's oesophagus: longterm follow-up after complete ablation with argon plasma coagulation and the factors that determine its recurrence. Aliment Pharmacol Ther. 2007;25:835-840.
31. Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc. 1996;44:532-535.
32. Sampliner RE, Camargo L, Fass R. Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus. Am J Gastroenterol. 2002;97:270-272.
33. Kovacs BJ, Chen YK, Lewis TD, DeGuzman LJ, Thompson KS. Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression. Gastrointest Endosc. 1999;49:547-553.
34. O'Connell K, Velanovich V. Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett's esophagus. Surg Endosc. 2011;25:830-834.